About us

Quick Facts

  • Established by the employees and management in 2015 through a buy-out from Takeda
  • Backed by a governmental investment fund and a team of Norwegian family offices
  • Strong growth in the international Contract Development and Manufacturing Organization (CDMO) market
  • Our values: Flexible, enthusiastic, trustworthy and courageous

 

History and ownership

Curida was established when a group of employees and management acquired the Takeda manufacturing site in Elverum, Norway in 2015. The acquisition followed Takeda’s decision to shut the site down and move all manufacturing to other parts of Europe. The manufacturing site, which has existed since 1974, had been part of Nycomed until 2011.

Under Takeda, the Elverum site had around 200 employees and was the largest private employer of the area. Curida started out with a smaller operation at its inception in 2015. Since then the site has experienced significant growth in terms of both revenue and employment, and it will in the near future approach the size it saw at its historic peak in 2013.

The employees showed great courage when starting their own company under uncertain conditions in 2014 and 2015. Before Norwegian Prime Minister Erna Solberg reopened the Elverum site under the Curida name on July 1st 2015, the employees had put more than 10,000 hours of volunteer work into making the new company a reality.

The employees and management remained the only owners of Curida until December 2017, when Norwegian family offices Canica and Klaveness Marine invested in Curida. Shortly after, the Norwegian governmental investment fund Investinor and family office Stokke Industri followed. The employees and management still control more than 20 percent of the shares in Curida.

In 2018, to increase the Norwegian footprint, Curida acquired Ås Produksjonslab, located south of Oslo. Ås Produksjonslab performs fill and finish of bottle products for the Norwegian pharmacy market.

 

A growth journey

Curida has built a diversified portfolio of customers in the international pharma market. The Elverum site currently exports to more than 80 countries. Curida is on a growth journey where revenue and manufacturing volumes increase significantly every year. The strong growth is expected to continue in the coming years, as a series of products is currently being added to the Curida portfolio through technology transfer and product development projects.

Curida’s ambition is to get a larger footprint in the international CDMO market, and we will continue to pursue growth opportunities. Through that, we want to contribute to strengthening the Norwegian healthcare industry and providing exciting jobs in the sector. We also believe that as a strong CDMO, we can work with authorities and business partners to ensure safe supply of important medicines.